NIPH Clinical Trials Search

JRCT ID: jRCT1070200115

Registered date:17/03/2021

A clinical research to assess correlation between transverse abdominal muscle contraction and pelvic floor muscle contraction in female subjects with stress urinary incontinence

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedstress urinary incontinence
Date of first enrollment06/05/2021
Target sample size30
Countries of recruitment
Study typeInterventional
Intervention(s)This study consists of two visits. After obtaining the informed consent from subjects, prespecified clinical test will be carried out in eligible subjects (Visit 1). On Visit 2, contractions of the transverse abdominal muscles and the pelvic floor muscles will be measured with electromyograph under pelvic floor muscles contraction condition. This measurement can be completed on Visit 1.


Primary OutcomeContraction data of the transverse abdominal muscles and the pelvic floor muscles obtained from electromyograph
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 65age old
Include criteria1.Subject has a clinical diagnosis of stress urinary incontinence, confirmed by a positive cough stress test or pad test at screening. 2.Subject has a body mass index range of 18.5 to 25.0 kg/m^2, inclusive. 3.Subject must either: i.Be of non-childbearing potential: a.Postmenopausal (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or b.Documented surgically sterile (e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). ii.Or, if of childbearing potential: a.Agrees not to try to become pregnant during the study b.And agrees to have a urine pregnancy test on screening and test visit. c.And have a negative urine pregnancy test at the screening visits d.And agrees to consistently use 1 form of highly effective birth control in the case of having heterosexual intercourse starting at screening and throughout the study period 4.Subject can contract pelvic floor muscles and it should be confirmed by ultrasound at screening and test date. 5.Subject agrees not to participate in another interventional study while participation in the present study.
Exclude criteria1.Subject underwent abdominal surgery at any time prior to screening. A prior caesarian section is allowed if performed more than 12 months prior to screening. 2.Any invasive procedures or surgery involving the pelvis and urinary tract, including bladder surgery (e.g., bladder augmentation or reduction surgery, latissimus dorsi detrusor myoplasty), pelvic organ prolapse surgery, and implant surgery for incontinence (e.g., tape, sling or artificial sphincter) at any time prior to screening. 3.Subject underwent pelvic radiation therapy at any time prior to screening. 4.Subject is using prohibited medications, or subject is using restricted medications under conditions different to those specified in the concomitant medication section. 5.Injection based treatment with botulinum toxin in the pelvis, bladder and/or abdominal muscles in the past 12 months. 6.Subject has a known diagnosis of pure urge incontinence, incontinence due to surgical treatment, or any significant voiding dysfunction (including nocturnal enuresis). 7.Subject has a known diagnose of a Chronic Pelvic Pain Syndrome e.g.,Bladder Pain Syndrome / Interstitial cystitis (BPS/IC). 8.Subject has any pain in the abdominal area that may affect outcomes, e.g., skin lesions, IBS, menstrual pain at Visit 2. 9.Subject has uterine prolapse >= Grade 2 Shaw's system (down to or outside the introitus), moderate or severe cystocele (reaches or protrudes outside the introitus). 10.Subject has a known diagnose of Diabetes Mellitus with related neuropathy. 11.Subject is known to have a Dermal Neuropathy like herpes zoster. And subject is known to have skin diseases or allergies at locations where electrodes will be attached. Local excision of skin lesions other than where the electrodes are attached is permitted. 12.Subject has clinical signs and symptoms of urinary tract infection, which is combined with a result of urine test (e.g., positive urine test by dipstick test). 13.Subject is known to have severe/complete SUI, i.e., subject is not able to hold urine. 14.Subject has a known neurologic disease or a defect affecting bladder function (e.g, neurogenic bladder, systemic or central neurological disease, such as Multiple Sclerosis or Parkinson's disease). 15.Subject has a known disease which is potentially responsible for incontinence known from medical history. This includes cardiac failure, chronic renal failure, uncontrolled diabetes, chronic obstructive pulmonary disease, stroke, dementia, general cognitive impairment, sleep disturbances (e.g., sleep apnea). 16.Subject is known to have diastasis recti abdominis and/or abdominal herniation (including inguinal, umbilical, femoral, and/or epigastric hernia). 17.Subject is known to have any condition, which makes the subject unsuitable for study participation. 18.Subject is employee of the Astellas Group, third parties associated with the study, or the clinical study site team. 19.Subject has received investigational therapy within 28 days or 5 times the half-live, whichever is longer, prior to screening.

Related Information


Public contact
Name Medical Information Center
Address 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo Tokyo Japan 103-8411
Telephone +81-120-189-371
Affiliation Astellas Pharma Inc.
Scientific contact
Name En Kimura
Address 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo Tokyo Japan 103-8411
Telephone +81-120-189-371
Affiliation Astellas Pharma Inc.